Unknown PHASE2 INTERVENTIONAL 3-arm NCT01036659

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema (ACE)

Evaluation of Ecallantide for Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Sponsor: Bernstein, Jonathan A., M.D.

Interventions ecallantide - Kallikrein inhibitor that blocks the production of bradykinin

Updated 6 times since 2017 Last updated: Mar 8, 2012 Started: May 31, 2010 Primary completion: Jun 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Angioedema and is currently ongoing. Bernstein, Jonathan A., M.D. leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bernstein, Jonathan A., M.D.
Dyax Corp.

Data source: Bernstein, Jonathan A., M.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States